MARKET OUTLOOK

NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Currently, physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. In this report, hepatologists reveal what attributes drive their prescribing and what they are looking for in terms of efficacy, safety, and delivery from future treatments. Using the Target Product Profile (TPP) simulator, we can establish physicians’ preference for emerging drugs and assess if these drugs can capitalize on the untapped NASH space.

QUESTIONS ANSWERED

  • How do hepatologists rate current NASH treatment options such as pioglitazone, vitamin E, and metformin?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What trade-offs across different clinical attributes and price are needed from new NASH drugs in order to be preferred over current treatment options?
  • How could obeticholic acid, elafibranor, and cenicriviroc meet the expectations of physicians treating NASH?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Three market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European hepatologists and gastroenterologists fielded in April 2019.

Key companies: Takeda, Merck KGaA, Intercept, Genfit.

Key drugs: Pioglitazone, vitamin E, metformin, ursodeoxycholic acid, statins, SGLT-2 inhibitors, GLP-1 receptor agonists.


Related Reports

Non-Alcoholic Steatohepatitis (NASH) | Disease Landscape and Forecast | G7 | 2020

The pharmaceutical market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has the potential to become lucrative owing to the current lack of appr...

View Details

Non-Alcoholic Steatohepatitis (NASH) | Unmet Need | US/EU | 2020

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at ri...

View Details